Monte Rosa Therapeutics is a clinical-stage biotechnology company pioneering molecular glue degrader (MGD) medicines. It pairs its QuEEN discovery engine — integrating artificial intelligence, machine learning, and structural biology — with proprietary chemistry to design small molecules that selectively degrade disease-causing proteins previously… - View it on GitHub